论文部分内容阅读
目的观察绝经后雌激素受体(ER)阳性乳腺癌患者行来曲唑新辅助内分泌治疗的效果。方法选取2013年6月至2015年6月饶平县人民医院收治的绝经后ER阳性乳腺癌100例患者的临床资料,按不同治疗方法分为两组,每组50例,对照组行他莫西芬新辅助内分泌治疗,观察组行来曲唑新辅助内分泌治疗,观察两组疗效。结果观察组总体有效率为92.00%,显著高于对照组的56.00%,且总体健康评分[(78.53±11.89)分]高于对照组[(64.37±10.02)分],差异均有统计学意义(P<0.05)。结论绝经后ER阳性乳腺癌患者行来曲唑新辅助内分泌治疗的效果显著,有利于病灶缩小,并提高生活质量,值得推广。
Objective To observe the effect of neoadjuvant endocrine therapy in patients with postmenopausal estrogen receptor (ER) positive breast cancer. Methods The clinical data of 100 patients with postmenopausal ER-positive breast cancer who were treated in Raoping People’s Hospital from June 2013 to June 2015 were divided into two groups according to different treatment methods, 50 cases in each group. Xifen neoadjuvant endocrine therapy, observation group letrozole neoadjuvant endocrine therapy, the two groups were observed. Results The overall effective rate in the observation group was 92.00%, significantly higher than that in the control group (56.00%), and the overall health score (78.53 ± 11.89) was higher than that in the control group (64.37 ± 10.02), the differences were statistically significant (P <0.05). Conclusions Letrozole neoadjuvant endocrine therapy is significantly effective in patients with post-menopausal ER-positive breast cancer, which is beneficial to lessening the size of the lesion and improving the quality of life, which deserves promotion.